Analysis and development trend of China's nutritional fat milk market

Fatty milk is an intravenous emulsion widely used in clinical intestinal nutrition support, with vegetable oil (the main component is fatty acid triglycerides) as the oil phase, supplemented by phospholipid emulsizers, iso-permeable agents and water-based emulsified water-based oil (
O/W
) emulsions. Pulse-injected fatty milk has two main functions: as the body's energy source and the provision of essential fatty acids.concept of fat milk began
the
1960s
the
1960s. At that time, western developed countries hospitals in order to save the lives of some critically ill patients, we must develop anon-rectal high-nutrition large infusionnew products, soybean oil because of a large number of lysic acid and acid and other long-chain fatty acid substances and become the best non-rectal high-energy raw materials, fatty milk vein applications opened a real meaning of the new era of extraintestinal nutrition.
1961
, scientists at Kabi Pharmaceuticals in Sweden used the new
"
high pressure homogenization
"
technology to produce qualified
"
sub-particle emulsified soybean oil for intravenous use Nutritional Infusion
"
product, which Carby named
Interlipid
," a registered product in China called
" "
, is still selling well today.
In
, Fessenyuscabi Holdings
51%
established a Sino-Swiss joint venture Huarui Pharmaceutical Co., Ltd.,
in 1986
, the company introduced Kabi's raw materials and patented production technology, officially put into production soybean oil fat emulsion
Interlipid
. After decades of development, there have been a variety of different composition of fat emulsions, long carbon chain fat milk, medium carbon chain
/
long carbon chain fat milk, structural fat milk,
omega-3
fatty acid fat milk, compound fat milk and so on.milk is a high-end product for large infusions. At present, China has become the world's first large intravenous infusion, but in the production of fat milk products is relatively slow development, many large infusion enterprises in glucose, sodium chloride and other basic infusion field cruel competition. Nutritional fatty milk in China's market size
5 billion
, the market concentration in this area is high. Domestic manufacturers of fatty milk are Huarui Pharmaceutical Co., Ltd., Guangzhou Baxter Overseas Chinese Light Medical Products Co., Ltd., Sichuan Colum Pharmaceuticals, Mitsubishi Pharmaceuticals (Guangzhou) Co., Ltd., Germany's Barang Shenyang Pharmaceutical Co., Ltd. and a series of companies, the production of structural fat milk manufacturers only Huarui Pharmaceuticals a company, and product key technology in the hands of foreign-funded enterprises. The top five companies in the sales were Beijing Fesenyus, Jiangsu Huarui, Bacao Light, Belang and Xi'an Libang, which together accounted for
94% of
's market share. Among them, Fessenjus and Warrie's market share reached
64%
more. Xi'an Libang, a purely local producer, has a
of 2.35%
.China's local enterprises imitation nutrition milk production mainly concentrated in the long-chain nutrition milk and medium-long-chain nutrition milk field, long-chain nutrition milk production approval
77
, medium-long chain nutrition milk approval
28
. Other types of nutritional fat milk are almost zero localized and are mainly held by Fessenyuscabi, Belang and Baxter. At present, the structured fat milk products widely used abroad in medicine are
Structolipid
and
FE73403
in Sweden, and the relevant products in the domestic market are mainly Liwen (Wary Pharmaceuticals, technology from The German company Fessenyuskabi). From the product price comparison, to Huarui company's products, for example, long-chain fat milk Indipit
20%-250mL
price in
85
yuan, medium-long carbon chain hybrid fat milk energy price in
20%-250 the
is about
90
yuan, while the price of structural fat milk
20%-250mL
is as high as
285
yuan, and the price of imported
FE734403
is higher.China
's aging population reached
13
billion by
2013, with an aging rate of
9.29%
, and the average growth rate of China's aging population in the past decade has exceeded


3.25%
. The increase of the aging population will bring about the demand for extraintestinal nutrients, and the demand for fatty milk as the main force of intravenous intestinal nutrition is bound to increase significantly.Special Medical Use Formula (
FSMP
) is specially processed to meet the special nutritional or dietary needs of people with restricted eating, digestive and absorption disorders, metabolic disorders or specific disease conditions. Special medical use formula food belongs to special dietary food, has been widely concerned by the Chinese people and even the world. At present, the world's annual consumption of special medical use formula food about
56-640
billion yuan, the market at an annual rate of
6
growth. Europe and the United States account for a larger proportion of annual consumption in the world, about
40-500
billion yuan, an annual growth rate of about
4.5%
. China accounts for
1%
of the global market for special medically used formulated foods, amounting to about
6
60 billion yuan, but has achieved rapid growth in recent years, with an average annual growth rate of more than
37%
. China's
FSMP
per capita consumption of less than
10,
yuan, while consumption in Europe and the United States reached
100,
yuan, if China's consumption level reached European and American standards, it will produce nearly 100 billion large markets. With
of FSMP
, fatty milk as a nutrient in the intestine also has great market potential.